Urorec Uniunea Europeană - slovenă - EMA (European Medicines Agency)

urorec

recordati ireland ltd - silodozin - hiperplazija prostate - urološki - zdravljenje znakov in simptomov benigne hiperplazije prostate (bph).

Zykadia Uniunea Europeană - slovenă - EMA (European Medicines Agency)

zykadia

novartis europharm limited - ceritinib - karcinom, pljučni pljuč - antineoplastična sredstva - zdravilo zykadia je indicirano za zdravljenje odraslih bolnikov z anaplastičnim limfom-kinaznim (alk) pozitivnim napredovalim nedrobnoceličnim pljučnim rakom (nsclc), ki je bil predhodno zdravljen s krizotinibom.

Silodyx Uniunea Europeană - slovenă - EMA (European Medicines Agency)

silodyx

recordati ireland ltd - silodozin - hiperplazija prostate - urološki - zdravljenje znakov in simptomov benigne hiperplazije prostate (bph).

Rubraca Uniunea Europeană - slovenă - EMA (European Medicines Agency)

rubraca

pharmaand gmbh - rucaparib camsylate - ovarijske neoplazme - antineoplastična sredstva - rubraca is indicated as monotherapy for the maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. rubraca je označen kot monotherapy za vzdrževanje zdravljenje odraslih bolnikov s platino-občutljive relapsed visoko-kakovostni razred epitelnih jajčnikov, fallopian tube, ali primarni trebušno raka, ki so v odziv (popolna ali delna) platinum, ki temelji kemoterapijo.

Verzenios Uniunea Europeană - slovenă - EMA (European Medicines Agency)

verzenios

eli lilly nederland b.v. - abemaciclib - neoplazme dojke - antineoplastična sredstva - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.

Silodosin Recordati Uniunea Europeană - slovenă - EMA (European Medicines Agency)

silodosin recordati

recordati ireland ltd - silodozin - hiperplazija prostate - urologicals, alfa-adrenoreceptor antagonisti - zdravljenje znakov in simptomov benigna hiperplazija prostate (bhp) pri odraslih moških.